[1] Yadav BS,Sharma SC,Patel FD,et al.Gynecological cancer as a second malignancy in patients with breast cancer[J].Int J Gynecol Cancer,2017 ,27(6):1298-1304. [2] Esselen KM,Cronin AM,Bixel K,et al.Use of CA-125 tests and computed tomographic scans for surveillance in ovarian cancer[J].JAMA Oncol,2016,2(11):1427-1433. [3] Pradjatmo H,Pradjatmo H.Impact of Preoperative serum levels of CA 125 on epithelial ovarian cancer survival[J].Asian Pac J Cancer Prev,2016,17(4):1881-1886. [4] Moore KN,Borghaei H,O'Malley DM,et al.Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853),a folate receptor α-targeting antibody-drug conjugate,in patients with solid tumors[J].Cancer,2017,123(16):3080-3087. [5] 龚哲,尚闯,单国用,等.微小RNA-200a在肝癌患者血清及癌组织中的表达及其与预后的关系[J].中华实验外科杂志,2015,32(3):608-610. [6] Toffoli G,Cernigoi C,Russo A,et al.Overexpression of folate binding protein in ovarian cancers[J].Int J Cancer,1997,74(2):193-198. [7] Peters IT,Hilders CG,Sier CF,et al.Identification of cell-surface markers for detecting breast cancer cells in ovarian tissue[J].Arch Gynecol Obstet,2016,294(2):385-393. [8] Mantovani LT,Miotti S,Ménard S,et al.Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19[J].Eur J Cancer,1994,30A(3):363-369. [9] Kalli KR,Oberg AL,Keeney GL,et al.Folate receptor alpha as a tumor target in epithelial ovarian cancer[J].Gynecol Oncol,2008,108(3):619-626.
2018, Vol. 35 
